Tarceva Approved in the EU for Advanced Non-Small Cell Lung Cancer

OSI Pharmaceuticals, Inc. announced Thursday that its international partner for Tarceva (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.
iStockAnalyst